Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 29, 2014		Jun. 30, 2013		Jun. 29, 2014		Jun. 30, 2013
Segment Reporting Information [Line Items]
Revenues	$ 12,773		$ 12,973		$ 24,126		$ 25,383
Earnings(a)	4,003	[1]	5,357	[1]	6,850	[1]	9,082	[1]
Global Innovative Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	3,547		3,726		6,623		7,032
Earnings(a)	2,009	[1]	2,320	[1]	3,776	[1]	4,215	[1]
Global Vaccines, Oncology and Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues	2,579		2,263		4,753		4,453
Earnings(a)	1,157	[1]	1,063	[1]	2,214	[1]	2,058	[1]
Global Established Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	6,513		6,921		12,503		13,782
Earnings(a)	4,176	[1]	4,409	[1]	8,225	[1]	8,861	[1]
Reportable Segments [Member]
Segment Reporting Information [Line Items]
Revenues	12,639		12,910		23,879		25,267
Earnings(a)	7,342	[1]	7,792	[1]	14,215	[1]	15,134	[1]
Other operating segment and other business activities [Member]
Segment Reporting Information [Line Items]
Revenues	63	[2]	63	[2]	119	[2]	116	[2]
Earnings(a)	(713)	[1],[2]	(671)	[1],[2]	(1,380)	[1],[2]	(1,331)	[1],[2]
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues	0	[3]	0	[3]	0	[3]	0	[3]
Earnings(a)	(1,287)	[1],[3]	(1,437)	[1],[3]	(2,487)	[1],[3]	(2,771)	[1],[3]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues	0	[3]	0	[3]	0	[3]	0	[3]
Earnings(a)	(949)	[1],[3]	(1,108)	[1],[3]	(1,957)	[1],[3]	(2,327)	[1],[3]
Acquisition-related Costs [Member]
Segment Reporting Information [Line Items]
Revenues	0	[3]	0	[3]	0	[3]	0	[3]
Earnings(a)	(47)	[1],[3]	(113)	[1],[3]	(77)	[1],[3]	(203)	[1],[3]
Certain significant items [Member]
Segment Reporting Information [Line Items]
Revenues	71	[4]	0	[4]	128	[4]	0	[4]
Earnings(a)	(238)	[1],[4]	1,012	[1],[4]	(1,254)	[1],[4]	924	[1],[4]
Other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues	0		0		0		0
Earnings(a)	$ (105)	[1]	$ (118)	[1]	$ (210)	[1]	$ (344)	[1]

[1] Income from continuing operations before provision for taxes on income.

[2] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[3] "Other Costs and Business Activities" section above.

[4] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Revenues in the second quarter and first six months of 2014, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2B. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Divestiture.For Earnings in the second quarter of 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $9 million, (ii) charges for certain legal matters of $4 million, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $212 million and (v) other charges of $31 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions—Net.For Earnings in the second quarter of 2013, certain significant items includes: (i) patent litigation settlement income of $1.4 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $185 million, (iii) certain asset impairments and related charges of $95 million, and (iv) other charges of $59 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions—Net.For Earnings in the first six months of 2014, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $17 million, (ii) charges for certain legal matters of $698 million, (iii) certain asset impairments and related charges of $114 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $346 million and (v) other charges of $113 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions—Net.For Earnings in the first six months of 2013, certain significant items includes: (i) patent litigation settlement income of $1.4 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $400 million, (iii) net credits for certain legal matters of $100 million, (iv) certain asset impairment charges of $489 million, (v) the gain associated with the transfer of certain product rights to our 49%-owned equity-method investment in China of $459 million, (vi) costs associated with the separation of Zoetis of $18 million and (vii) other charges of $79 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions—Net.